Correspondence: Dario Siniscalco, Department of Experimental Medicine, University of Campania, Via S. Maria di Costantinopoli 16, 80138 Naples, Italy, Tel +39 eighty one 566 5880, Email dariosin@uab.edu

Collection date 2018.

The full terms of this license are available at https://www.dovepress.com/phrases.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-business uses of the work are permitted without any additional permission from Dove Medical Press Limited, supplied the work is properly attributed.

Autism spectrum disorders (ASDs) are characterized by core domains: persistent deficits in social communication and interplay; restricted, repetitive patterns of behavior, interests, or actions. ASDs comprise heterogeneous and complex neurodevelopmental pathologies with nicely-defined inflammatory circumstances and immune system dysfunction. As a result of neurobiologic modifications underlying ASD development, cell-based therapies have been proposed and utilized to ASDs. Indeed, stem cells show particular immunologic properties, which make them promising candidates in ASD therapy. This complete up-to-date assessment focuses on ASD cellular/molecular abnormalities, potentially useful stem cell sorts, animal fashions, and present clinical trials on the use of stem cells in treating autism. Limitations are also discussed.

Keywords: autism spectrum disorder, stem cell, cell therapy, immune dysfunction

Autism spectrum disorders (ASDs)

ASDs are very attention-grabbing neurodevelopmental disorders for the medical and scientific group, because of their multifactorial nature and many different explanations for their clinical heterogeneity.1 ASD patients display extremely diverse groups of disorders with huge variation in symptoms, mental stage, severity, and purposeful incapacity.2 The variation is due partly to its multifactorial origin that leads ASD to be a neurogenetic clinical entity3,four with gastrointestinal,5,6 immunologic,7,8 and metabolic implications9 that start within the womb. ASDs are multistage, progressive disorders of brain development and synapse connections, spanning practically all of pre- and postnatal life.1 ASD starts on the first embryonic levels with disruption of cell proliferation and differentiation, which ends up in a sequence of sequential events like neural migration, laminar disorganization, altered neuron maturation, neurite outgrowth, issues of synaptogenesis, and reduced neural community functioning.1

ASD affects greater than 1% of the final inhabitants (1:Fifty nine subjects)10 and are characterized by two core signs: the first one is impaired social communication, and the second situation is restricted, repetitive forms of conduct, interests, or activities. However, the biggest drawback in autism is triggered by related symptoms equivalent to irritability, anxiety, aggression, compulsions, mood lability, gastrointestinal points, depression, and sleep disorders.11 On the premise of the core and related signs, autism is diagnosed through observational and psychometric exams; therefore, the clinical diagnosis is made based mostly on the presence or absence of core behaviors. The Diagnostic and Statistical Manual of Mental Disorders is conventionally used as a gold standard for autism prognosis.12 However, the neurometabolic differences of autism lead us to look for biologic markers that respond to a correct, exact, and concise prognosis.Thirteen These biologic markers must be detected early during pregnancy, because the pathogenesis of ASD just isn't set at one point in time and does not reside in one course of, but fairly is a cascade of pre- and postnatal pathogenic processes within the vast majority of ASD toddlers.1

The treatment of ASD is variable and multimodal. It's composed of conventional therapies, resembling social abilities training, early intensive conduct therapy, applied behavior analysis, speech therapy, occupational therapy, along with psychotropic medicine,14 transcranial magnetic stimulation,15 and various treatments, which include hyperbaric oxygen remedy,sixteen music therapy, and cognitive and social behavioral therapy.17 Hormonal therapies with oxytocyin have additionally shown some guarantees in bettering central ASD symptoms.18 The usage of vitamins, herbals, essential oils, and nutritional supplements19,20 and typical therapies have some effect in symptomatic enchancment in ASD, though additional research are wanted to confirm these benefits. Developing novel therapies may show to be the final word intervention for sustained improvement of signs in ASD.17 Among the brand new therapies out there, there are the gene therapy and stem cell therapy, which have nice potential for treating ASD.21,22 The redesign of brain architecture, generated from reprogrammed somatic cells isolated from living patients, supplies new insights into the understanding of autism and thus reverses or ameliorates the symptoms of disorder. Here, we focus on latest advances in using stem cells as a therapy of ASD, as well as its limitations, implications, and future prospects.

Stem cells for neurologic diseases

The chance to face neurologic diseases and ASD specifically with stem cell software is described on this part.

Neurologic diseases are often irreversible as a result of gradual and limited neurogenesis in the mind.23 Therefore, primarily based on the regenerative capability of stem cells, transplantation therapies of varied stem cells have been examined in basic analysis with animal fashions, and preclinical and clinical trials, and many have proven great prospects and therapeutic promises.23 Comparative studies have been raised to know nature, properties, and number of donor stem cells, the delivery mode, and the choice of proper affected person populations that may benefit from cell-based therapies.24

However, many times these features don't enable to predict why there isn't any appropriate animal model for the research of certain diseases of neurologic growth. Animal models of complex immunogastrometabolic phenomena, such because the ASD, are difficult to validate. The reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) could provide an alternative technique for identifying the cellular mechanisms contributing to autism and the event and testing of many new remedy options.25 This facet can be defined at the end of this evaluate as a result of it accommodates the key to success of the therapy of stem cells in autism.

Mechanisms underlying therapeutic impact

No less than two key-motion mechanisms of stem cells could possibly be useful for ASD therapy: paracrine impact (the secretome device: cytokines, chemokines, and development components released by stem cells and accountable of restore/restoration of injured tissues) and immunomodulatory properties.22 ASDs show immune system abnormalities and strong proinflammatory cytokine production.26,27 ASD topics present an imbalance in innate and adaptive immunity, as CD3+, CD4+, and CD8+ T cells, as well as pure killer (NK) cells, are altered.27 Immune alterations in ASDs are still confirmed by abnormal monocyte and macrophage responses, which overproduce proinflammatory IL-1β cytokine and show several altered molecular programs resulting in long-term immune alterations.8,26,28-30 The immune modulatory capability of stem cells might restore these ASD-immune alterations. Stem cells are capable of strongly inhibit CD8+ and CD4+ T lymphocytes and NK cell overactivation and proliferation by inhibiting proinflammatory tumor necrosis factor alpha and interferon gamma molecules and increasing anti-inflammatory IL-10 levels.31 This truth is confirmed by an animal model of autism, by which stem cells, as soon as transplanted, were ready to increase anti-inflammatory cytokine production (detailed in Stem cells and autism: animal models section). The power to modulate the immune system by stem cells is mediated through soluble components released by stem cells underneath local chemical surroundings signaling.32 Another proposed mechanism by which stem cells are in a position to handle the ASD-mediated immune and inflammatory abnormalities is the cell-to-cell contact activation mechanism, by which stem cells are able to switch proinflammatory cells to anti-inflammatory ones.22,32

Table 1 summarizes the dangerous processes of ASD that might be contrasted by stem cell’s own capacities. The following section will explain the potential use of specific stem cell sorts for ASD.

Diagrammatic representation of different stem cells and associated sources for the treatment of autism and their mechanisms of motion

Note: Homing and mobility capacities are frequent for all the stem cell sorts.

Abbreviations: VEGF, vascular endothelial growth factor; HGF, hepatocyte growth issue; BDNF, brain-derived neurotrophic factor; NGF, nerve development factor.

Stem cell varieties

Several kinds of stem cells have been described. The next section exhibits every kind with potential use for the therapy of ASDs.

Fetal stem cells (FSCs)

FSCs are found at numerous levels of human growth and can be isolated from numerous somatic organs of fetus, fetal blood, and quite a lot of extraembryonic sources like placenta, amniotic membrane, amniotic fluid, and umbilical cord. FSCs have properties that lie in between the embryonic and adult stem cells that they self-renew faster in tradition, have higher differentiation potential and high engraftment rate, and do not type teratomas in vivo.33

Fetal SCs from bone marrow categorical pluripotent markers like Oct-4, Nanog, Rex-1, SSEA-3, SSEA-4, Tra-1-60, and Tra-1-eighty one and present greater telomerase exercise, which makes them a preferable candidate for therapeutic applications.33 For treating neurodegenerative diseases, neural stem cells (NSCs) from totally different components of the fetal brain have been explored. The fetal NSCs have the power to self-renew and are multipotent with the ability to differentiate into neurons, astrocytes, and oligodendrocytes.34-36 FSCs have the ability to secrete numerous neurotrophic and immunomodulatory components that promote neuronal development and suppress the action of proinflammatory cytokines that make them a potential candidate for treating ASDs and various neurodegenerative diseases.37

There are various reviews on the profitable use of FSCs for different neurodegenerative disorders. When the fetal NSCs were transplanted into the rat fashions of temporal lobe epilepsy and ischemia, they get grafted and differentiated into neurons.34,35 A clinical trial in younger human Parkinson’s patients additionally showed promising outcomes when dopamine neurons from fetal neural tissues have been transplanted.36 An open-labeled clinical trial that examined the security and efficacy of FSCs in autistic children revealed no opposed events and a major difference in the advance of autistic symptoms (detailed in Stem cells and autism: animal fashions part).37

Bone marrow-derived stem cells

Mesenchymal stem cells (MSCs)

MSCs are present in nearly all of the adult tissues and are characterized by their skill to adhere to plastic surface, express cell surface antigens like CD105, CD90, and CD73, not categorical CD34, CD45, CD14 or CD11b, CD79α or CD19, and HLA-DR, and differentiate into osteoblasts, chondroblasts, and adipocytes in tradition.38 Aside from these minimal traits, MSCs have wider properties like their skill for speedy proliferation, differentiation into cell forms of endodermal and ectodermal origins, secretions of assorted tropic components, and immunomodulatory action, which make them a preferable candidate for cellular therapies.39,forty

The paracrine secretion and immunomodulatory properties of MSCs make them a possible candidate for treating ASDs.41 Cultured MSCs secrete various neurotrophic components together with vascular endothelial progress factor (VEGF), hepatocyte growth issue, brain-derived neurotrophic factor (BDNF), and nerve growth factor and exhibit neuroprotective results.42 MSCs are additionally hypoimmunogenic and have immunosuppressive properties that they don't categorical co-stimulatory molecules akin to CD80, CD86, or CD40 and categorical low levels of MHC class I molecules.43,44 Different mechanisms had been hypothesized for utilizing MSCs for treating ASDs that include inducing plasticity, secretion of anti-inflammatory and survival-selling components, and engrafting into neural community.45

Also, in vivo, in different animal fashions of neurodegeneration, MSCs exert neuroprotection primarily by secretion of assorted neurotrophic and immunomodulatory factors, thus facilitating the recruitment of endogenous stem cells to advertise regeneration and by downregulating T cells, B cells, and NK cells of immune system.46 Owing to those properties, MSCs have been highly most well-liked candidates for clinical trials for varied neurologic diseases. Clinical trials utilizing MSCs are ongoing for diseases like multiple sclerosis (MS), stroke, Parkinson’s illness (PD), Huntington’s illness (HD), Alzheimer’s illness (Ad), and systemic autoimmune diseases.Forty seven For ASDs, several studies using stem cells have been performed in people (detailed in Stem cells and autism: animal fashions section); a research by Lv et al analyzed the security and efficacy of utilizing human cord blood mononuclear cells (CBMNCs) and umbilical cord-derived mesenchymal stem cells (UCMSCs) in treating kids with autism.Forty eight They reported protected and statistically vital enhancements in the Childhood Autism Rating Scale (Cars), Clinical Global Impression (CGI) scale, and Aberrant Behavior Checklist (ABC) within the children handled combinedly with CBMNCs and UCMSCs when in comparison with the management group.

Adipo-stem cells

Stem cells may also be remoted from completely different adipose tissues in the physique in a minimally invasive manner and are termed as adipose-derived stem cells (ASCs). Much like MSCs, ASCs are plastic adherent, categorical CD90, CD105, CD73, CD44, and CD166, lack the expression of CD45 and CD34, and have the ability to differentiate into cells of all three germ layers.49,50

Along with being multipotent, ASCs secrete numerous trophic factors and are immunosuppressive and hypoimmunogenic, making them a lovely candidate for cellular therapies. ASCs have been used in varied clinical trials focusing on a wide range of indications ranging from immune disorders, myocardial infarction, bone defects, and neurodegenerative diseases. Although no experiences have been discovered on the use of ASCs for treating ASDs, ASCs have been proven effective in other neurologic preclinical fashions, as in the mouse mannequin of middle cerebral artery occlusion, human ASCs partially rescue the stroke syndromes by forming new neurons and blood vessels and rising the viability of endogenous neurons.Fifty one

Umbilical cord- and amniotic fluid-derived stem cells

Umbilical cord and placenta additionally offer a superb source of stem cells.22 These stem cells offer sturdy potential therapeutical applications and show mesenchymal traits.Fifty two The Wharton Jelly of the umbilical cord and the amniotic fluid are different sources of stem cells possessing excessive in vitro progress capability and low immunogenicity and immunomodulation properties, expressing the typical antigen profile of MSCs.53,fifty four These cells from perinatal, extraembryonic tissue have potential for future purposes in ASDs.22 There are not any moral controversy and danger of teratoma formation, and so they may be used for autologous transplantation after banking in later levels of life.55

NSCs

NSCs are discovered in the fetal and grownup human brain and have the potential for extensive proliferation and differentiation into three major cell varieties of the nervous system, the neurons, astrocytes, and oligodentrocytes.56 The NSCs that can be extracted from two major areas of the mind, namely, the subventricular zone of lateral ventricles and subgranular zone of hippocampus, could be cultured.57,58 The tradition-expanded NSCs are multipotent, have the ability to differentiate into various neuronal cell types, secrete neurotrophic components, integrate into neural tissue, maintain homeostasis, and are neuroprotective, making them a perfect candidate for treating ASDs. Indeed, impairments in excitatory and inhibitory cortical neurons lead to minicolumn construction abnormalities in ASDs.56 Synaptic-associated genes show a number of rare variants in some ASD topics.59 Provided that, transplantation of NSCs might be efficient in ASDs, as transplanted cells can promote neural tissue restore and homeostasis by means of integration in damaged areas and secretion of things that improve brain restore and plasticity.60 The definitive use of NSCs for clinical applications in neurodegenerative diseases still requires addressing some essential points: autologous dependable supply of ample quantity of stem cells must be recognized; submit-transplanted neural plasticity and differentiation, if any, must be further defined.60 However, although NSCs have been used in numerous preclinical and clinical research against completely different neurologic circumstances like PD, HD, Ad, amyotrophic lateral sclerosis (ALS), MS, stroke, and spinal cord damage (SCI), the result will not be definitive as anticipated and is hindered by several points to be further elucidated: the absence of homogenous cell population, stability, and long-term survival of neurons after transplantation.61,62

Different methods have been tried to enhance the capabilities of NSCs, like immortalizing the NSCs by gene manipulation methods to create a homogenous, long-surviving cell that is able to differentiating into neurons and glial cells when transplanted into regular or damaged brain.58

Hematopoietic stem cells (HSCs)

HSCs are primarily resident in bone marrow and likewise in blood and umbilical cord. Specific cluster of differentiation markers characterize them (CD34, CD59, CD117, CD133, CD164).63 Self-renewal, multipotency, and homing/mobility activities are very excessive. This kind of stem cells is ready to differentiate in myeloid and lymphoid lineages. Their paracrine activity, releasing bioactive molecules, and their capability to rapidly site visitors to the positioning of inflammation gained them quite a lot of attention for his or her use in ASD therapy.Sixty three Several clinical trials have been carried out with the usage of CD34+ stem cells in autism (detailed in Stem cells and autism: animal models section).

iPSCs: the brand new frontier for cell therapy

iPSCs could signify a novel tool for ASD therapy.

iPSCs are relatively new type of stem cells which can be reprogrammed from any cell kind of the body by ectopic expression of various transcriptional components initially by utilizing integrating vectors like retroviruses and lentiviruses. The iPSCs derived by these methods pose risk of insertional mutagenesis and make them unsafe for therapeutic functions. To beat this obstacle, numerous new strategies like use of small molecules, sendai virus, adenovirus, RNA molecules synthesized by plasmids, and recombinant proteins have evolved to create integration-free iPSCs.64 The iPSCs derived from different methods have the traits just like that of embryonic stem cells, having the ability to self-renew, categorical stem cell markers, and differentiate into the cell of all of the three germ layers except the cells in additional-embryonic tissue. The main benefit of iPSCs over the ES cells is their straightforward method of derivation from any cell sort with out the need for embryos and that they function an unlimited cell source for autologous therapy. iPSCs derived from the donors have many functions other than being used for regenerative therapies, and the affected person-specific iPSCs are used in disease modeling, toxicity testing, and drug screening research.Sixty four

Disease-specific iPSCs derived from patients function an infinite supply for drug testing research. A variety of iPSCs are produced from patients suffering from unifactorial and multifactorial diseases starting from adenosine deaminase deficiency-associated extreme combined immunodeficiency, PD, HD, ALS, Down syndrome, type 1 diabetes, Duchenne muscular dystrophy, spinal muscular atrophy, and β-thalassemia65 that serve as a model for disease and for drug testing on them.

With regard to therapeutic usage, iPSCs are viewed as a possible candidate for treating various disorders. The proof to substantiate the usage of iPSCs for clinics comes from numerous in vitro and in vivo preclinical trials. In in vitro, iPSCs might be made to differentiate into varied cell types like dopamine and motor neurons, dendritic cells, practical cardiomyocytes, macrophages, hepatocytes, and hematopoietic and endothelial cells.66 There are a number of in vivo studies that prove the efficiency of iPSCs in treating neurodegenerative disorders, cardiovascular disease, and sickle cell anemia. For example, in contusive SCI mannequin in nonobese diabetic severe combined immunodeficient mice, injection of neurospheres derived from human iPSCs leads to recovery of locomotor operate with out formation of any tumors.67 The differentiation capabilities of injected neurospheres into neurons, astrocytes, and oligodendrocytes along with induction of angiogenesis, axonal regeneration, and native-circuitry reconstruction could contribute to the restoration in SCI mannequin.67 When autologous iPSCs-derived dopamine neurons had been transplanted in PD model of cynomolgus monkey, the neurons engraft and survive for extended time of two years leading to improvement within the motor operate in the nonhuman primate model.68 iPSCs have additionally been used effectively against HD and ALS by their capability to differentiate into desired neuronal lineages.69,70

Despite the promising in vitro and preclinical studies, the usage of iPSCs in clinical trials is still in infant stage. There are some major challenges like tumorigenicity and immunogenicity to be addressed earlier than using iPSCs for clinical purposes. iPSCs used for transplantation may lead to teratoma formation: any residual pluripotent stem cells in grafting experiment could induce teratoma. This issue can be addressed by growing more efficient nonintegrative approaches for deriving iPSCs, utilizing differentiated cells fairly than iPSCs and in addition by prior screening and number of cells before transplantation.71 For immunogenicity issue, although largely iPSCs are used in autologous vogue there are some evidences that confirmed that iPSCs and cells derived from iPSCs can still elicit little immune response in syngeneic recipients that once more may be overcome by improved reprogramming technologies.Seventy two

iPSC applications gain much attention additionally for autism analysis.Seventy three Successful reprogramming of peripheral blood-derived mononuclear cells from autistic little one into iPSCs has been carried out by transgene-free delivery system.Seventy four Customized iPSCs will help in elucidating the pathogenic mechanisms of ASDs,seventy five also for neuronal differentiation and maturation.76 Indeed, iPSC-derived neurons from autistic topics show aberrant cation channels expression, voltage-gated currents, and modifications in synaptic functions.77,78 Autistic patient-derived stem cells show an altered developmental neuronal phenotype: alteration in cell our bodies, branched neurites, and motility in contrast with those derived from controls.79 Using iPSCs to generate three-dimensional fashions of neurons and brain structures may be useful to mannequin autism pathophysiology.Eighty

Stem cells and autism: animal fashions

Animal models are taking part in a vital role in exploring the potential of stem cells for growing therapeutic strategies for ASDs and can provide novel insights via which stem cells can help in ameliorating ASD-associated phenotypes. These information cannot be achieved by clinical trials.

As lifelong neurodevelopmental pathologies, ASDs are uniquely human behaviors and animal fashions fail to completely reproduce the human condition; however, they might present some important basic data.Eighty one A commonly used rodent model for ASD is the black and tan brachyuric (BTBR) inbred mouse strain. BTBR mice spontaneously develop behavioral deficits and brain abnormalities reflecting ASDs. Human MSCs have been intracerebroventricularly transplanted (50,000 cells/µL) in BTBR mice.Eighty two Cell therapy improved repetitive behaviors in transplanted mice by means of lowering digging and self-grooming duration and rising the latency between two consecutive occasions. Cell-transplanted mice additionally displayed decreasing in cognitive rigidity as measured by water T-maze check. To notice, social conduct was additionally improved: transplanted BTBR mice reported better social method and social novelty desire with respect to nontransplanted BTBR mice.Eighty two By a cellular perspective, hMSCs improved hippocampal neurogenesis (rising of Ki-67 and DCX markers) and increased BDNF ranges; after 6 weeks put up-transplantation, hMSCs had been discovered to be situated close to the wall of the dorsal third ventricle. In the same mouse mannequin, hMSC transplantation (50,000 cells/µL into the cerebral lateral ventricle) confirmed long-term helpful results in ameliorating autistic-like signs.83 Social behaviors have been improved and stereotypic behaviors have been decreased at 6 months posttransplantation. Another human stem cell kind, the ASCs (50,000 cells/µL, intraventricularly), was successfully used in valproic acid (VPA)-induced autism mouse mannequin.Eighty four Transplanted mice displayed increased motor coordination (as measured by open-subject test) and social behaviors and decreased anxiety. Human ASCs had been responsible to extend the phosphatase and tensin homolog, VEGF, IL-10 expression, and p-AKT/AKT ratio within the brains of VPA mice.Eighty four Mouse-derived MSCs had been utilized in VPA-induced autism mannequin, leading to increasing neurogenesis and promoting maturation of newly formed neurons in the dentate gyrus 2 months after transplantation.85 MSCs had been expanded in culture for up to 20 passages and immunophenotyped for mesenchymal specific markers. Then 1000's of MSCs in 5 µL MSC have been transplanted into the proper lateral ventricle. Deficits in cognitive and social behaviors have been additionally improved after 2 weeks posttransplantation.85

Beyond stem cell therapy as precious device for treating autism, stem cells additionally supply the likelihood for in-depth research of ASD pathology. Offspring of immune-activated mothers (maternal immune activation autism mannequin) develop preferential myeloid lineage potential and altered differentiation of HSCs.86 The importance of this work displays that immune modifications throughout maternal life may confer alterations in stem cells lineage through the complete life of offspring.

Transcriptome analysis revealed differential expressed genes in dental pulp stem cells from idiopathic ASD topics in comparison with controls.87 While stem cells may very well be used for understanding the biologic mechanisms of ASDs, the cellular adjustments of ASD-derived stem cells pose some considerations for autologous cell transplantation, as described further on this review.

Stem cells and autism: clinical trials

Clinical trials on stem cell transplantation in ASDs are of vital significance to validate security (in first) and the efficacy of the cellular therapy.

Currently, several clinical trials have been carried out to display security and efficacy of stem cells autism administration (Table 2). Sharma et al conducted an open-label proof-of-concept study on using autologous bone marrow-derived mononuclear cell (BMMNC) transplantation in 32 subjects (median age at intervention 10.5 years, male:female 3:1) with confirmed prognosis of autism.88 The protocol included intrathecal cellular therapy followed by occupational therapy, sensory integrative strategy, speech therapy, psychological intervention, and specific dietary suggestions. Mononuclear cell fraction is a heterogeneous mixture consisting of endothelial progenitors, HSCs and MSCs, and multipotent adult progenitor cells. These cells were separated from the aspirate of bone marrow, counted by CD34+ marker and checked for viability. On the identical day, the cells had been intrathecally injected and methyl prednisolone was given intravenously to reinforce survival of the injected cells. Long-time period antagonistic occasions were monitored to establish the security of stem cell transplantation. Minor antagonistic occasions (vomiting, nausea, ache at side of injection, or aspiration) had been current. These events had been reported to be procedure-related and not cellular transplantation-associated points. Minimal increase in hyperactivity was recorded as a significant adverse event associated to cell procedure, together with three patients developing seizures. After cellular therapy, Indian Scale for Assessment of Autism (ISAA) indicated enhancements in the domains of social relationships and reciprocity (improved eye contact, social smile, and reaching out to others), cognitive aspects (attention, concentration, and time of response), and in addition in speech and language patterns (discount in echolalic speech, partaking in stereotyped repetitive use of language, manufacturing of infantile squeals or unusual noises, inability to provoke or maintain conversation with others, inability to understand the pragmatics of the dialog, and speech regression). Decrease in inappropriate emotional responses, exaggerated feelings, engaging in self-stimulating emotions, and getting excited or agitated for no apparent purpose was recorded. CGI scale scored modifications in the severity of the disease, general improvement, and the efficacy of the therapy. Interestingly, purposeful neuroimaging, by the technique of positron emission tomography (PET) scan, showed elevated 18F-fluorodeoxyglucose (18F-FDG) uptake in the areas of frontal lobe, cerebellum, amygdala, hippocampus, parahippocampus, and mesial temporal lobe after 6 months of cellular therapy. Hypoperfusion has been just lately demonstrated in key mind areas of ASD subjects.89 Hypometabolic areas before cell transplantation confirmed elevated metabolism after cellular delivery, most likely as a result of improved oxygenation and functioning of the broken neurons. As limitations, authors report the small sample measurement, and the absence of randomization and a control group.88

Table 2.

Clinical trials performed on the usage of stem cells in ASDs

Most lately, Sharma et al carried out this kind of cellular remedy on a male autistic grownup (25 years previous).90 Autologous BMMNCs had been intrathecally transplanted. No major antagonistic occasions had been seen. After 6 months of cellular therapy, enhancements in concentration, sitting tolerance, attention, sleep, eye contact, social interactions, and memory had been reported, as measured by ISAA, Cars, and Functional Independence Measure scores before and after cellular treatment. Six months posttherapy, 18F-FDG PET scan confirmed improvements in mind hypometabolism.

Lv et al carried out a Phase I/II trial to analyze the safety and efficacy of mixed transplantation of CBMNCs and UCMSCs in treating youngsters with autism.Forty eight Thirty-seven autistic children (only one feminine) have been recruited and randomly subdivided in control (mean age 5.60) and experimental groups. This group was additional divided into CBMNC group (mean age 7.4) and mixed group (mean age 6.2) which received each varieties of cells. No opposed results were recorded on the time of transplantation and during the entire comply with-up. As minor effects, only 5 kids developed a transiently low-grade fever. About cell process, the cells had been remoted from gifted cord blood and umbilical cord of informed wholesome donors. CD34+ CBMNCs were extracted and in vitro grown in a GMP facility. After extraction from umbilical cord, UCMSCs were in vitro expanded and labeled for MSC characterization: CD29+, CD73+, CD90+, CD105+, the expression of CD45, CD34, CD14, CD79, and HLA-DR was absent or <2%. Cell viability, sterility, mycoplasma, and endotoxin presence were monitored. The cell transplantation protocol required four times cell administrations in both CBMNC and combination groups at an interval of 5-7 days.48 CBMNCs and UCMSCs were transplanted intravenously (20 mL) and/or intrathecally (2 mL), respectively, per treatment. After cellular therapy, CARS, CGI, and ABC reported significant improvements in stereotypic behaviors and lethargy/social withdrawal (improvements in visual, emotional and intellectual responses, body use, adaption to change, fear or nervousness, nonverbal communication, hyperactivity, and inappropriate speech).48 At the end of 24-week follow-up, best improvements were seen in combination group rather than CBMNC group, with respect to control group. Probably, the CBMNCs and UCMSCs exerted their positive actions synergically. Among limitations, enrolled subjects were not categorized on disease severity and long-term efficacy (beyond 24 weeks) was not evaluated.

In one other open-label pilot research, a complete of forty five autistic children (39 males, six females, imply age 6.9) had been enrolled to assess the security of using FSCs in ASDs.37 FSCs were harvested from 5- to 9-week-outdated human fetuses (one donor pattern for each transplantation procedure) following voluntarily selective pregnancy terminations. Donor ladies and fetal samples had been tested for bacterial, fungal, and viral infections and parasites. CD34+ HSCs had been extracted from fetal liver (a robust area of interest for HSCs)91 and brain and in vitro expanded. Colony-forming units and neurosphere formation have been checked. HSCs had been then saved in liquid nitrogen at −196°C within the cryobank and had been intravenously transplanted at day 1. On the second day, the fetal cells had been injected into the subcutaneous abdominal adipose tissues. ASD children handled with FSCs displayed no hostile occasions or unwanted effects as a result of cell therapy or steroid and antihistamine mixture pretreatment through the 1-12 months comply with-up interval studied. The early submit-cellular transplantation effects observed had been improved eye contact, appetite, and socialization. Autism Treatment Evaluation Checklist and ABC scores at observe-up occasions of 6 and 12 months confirmed improvements in sociability, cognitive capacity, and behaviors, particularly at the ultimate time point. To notice, pre- and publish-cellular therapy immunologic findings indicated an improved cell-mediated immunity, on account of a major increase of CD3+ T lymphocytes and CD4+ T helpers, and a lower in CD19+ B lymphocytes counts after the cellular remedy (pretreatment values had been abnormal). Fetal SC transplantation was protected and effectively tolerated. According to the authors, the administration routes (intravenous and subcutaneous) were chosen on the idea of their less invasivity. Immunomodulatory capabilities of FSCs seem to be a key mechanism of motion.37

Recently, Phase I/II results of a clinical trial on autologous umbilical cord blood (AUCB) transplantation in idiopathic ASD kids have been printed.Ninety two As crossover examine, ASD kids (age 2-7 years), with umbilical cord blood cryopreserved and saved, had been transplanted with either AUCB or placebo (0.9% saline solution), and evaluated at baseline, 12, and 24 weeks. The topics were randomly divided into two teams. The first group received cord blood infusion and then saline injection. The second group obtained saline infusion first, then cord blood infusion. Accordingly to the authors, the selection of the crossover research is that in this manner every subject serves as its personal control. As well as, the crossover design resulted in wonderful compliance by parents. Transplanted ASD children had been evaluated at 12 and 24 weeks posttransplantation. UCB was checked for sterility, viability, colony-forming unit, and CD34+ cell count. Some possible UCB therapy-related gastrointestinal disorders had been reported. No severe antagonistic events required treatment. CGI and Expressive/Receptive One Word Picture Vocabulary Tests scores reported minimal proof of clinical effectiveness of AUCB therapy. While crossover research provides the possibility to minimize the baseline variability, as limitations publish-thaw CFU capability and CD34+ count need to be higher addressed. Another point of dialogue is the exact AUCB dosage, varying amongst enrolled topics due to parental alternative in using personal biobanked UCB. This latter research reveals conflicting results in comparison with the Dawson research.Ninety three Twenty-five ASD children (21 males, four females, mean age 4.6 years) received a single intravenous infusion of AUCB. Sterility, infection disease markers, nucleated cell rely, CD34+ count, and CFU had been examined on biobanked UCB. A portion of or the complete personal cord blood unit (1-5 × 107 cells/kg) was infused per ASD subject. AUCB infusion was well tolerated, as no serious adverse effect was reported in any participant. Agitation, allergy, and skin changes have been reported as unrelated hostile effects. Vineland Adaptive Behavior Scale-II, CGI, Pervasive Developmental Disorder Behavior Inventory, and Expressive One-Word Picture Vocabulary Test-4 have been the primary assessments used to evaluate cognitive and behavioral improvements. Socialization, communication, and adaptive conduct scores had been improved at 6 months postinfusion and had been sustained between 6 and 12 months posttreatment.Ninety three Interestingly, nonverbal, higher IQ ASD kids showed greater enhancements in behaviors. However, as authors acknowledged, the noticed behavioral outcomes might be because of the pure course of development through the preschool period.

Limitations

Several limitations and recommendations have to be taken into account earlier than claiming definitive outcomes about cellular therapy in ASD.

Stem cell therapy provides novel alternative to develop cell-based drugs and functions to deal with a number of diseases, including immune and neurodegenerative pathologies,94 as well as ASD.22 It is crucial that cellular therapy is carried out under laboratory and clinical tips. The International Association of Neurorestoratology has lately revealed the Clinical Cell Therapy Guidelines for Neurorestoration.Ninety five These pointers situation the beneficial standards for personnel, facilities, and institutions that perform cell-based mostly therapies, in addition to the moral necessities, and embrace the provisions: patient-knowledgeable consent/IRB; indications/contraindications for cell therapy; documentation of procedure and therapy; safety and efficacy evaluations; policy of repeated treatments; not charging patients for unproven therapies; primary ideas of cell therapy; and publishing duty.Ninety five While the mechanisms of motion of stem cells are being explained by primary analysis, in addition to by in vivo models, clinical trials provide scientific effectiveness for human functions.96 However, from the clinical trials examined above (Table 2), several limitations must be taken under consideration, earlier than claiming definitive results for the usage of stem cells in ASD treatment.

Relatively small variety of subjects

The variety of enrolled subjects requires larger research on the usage of the cell therapy in ASDs. All the analyzed clinical trials admit the small pattern dimension used. Control group additionally needs to be more standardized.

Time of observe-up

Harmonization of the time of the study is fascinating. Long-term outcomes or the choice of multiple timely transplantations should be elucidated.

Efficacy

The efficacy of cell therapies in ASDs ought to be evaluated by internationally validated, standardized, and preferably harmonized scales. Too many various scales and scores, even when nicely adopted and established by worldwide scientific group, often do not show the effective results of cell transplantation.

Cell heterogeneity and culturing

A greater characterization of cell types used in all of the abovementioned research will help in the fitting choice of cell to be utilized. If the cells require in vitro enlargement before transplantation remains to be clarified. To note, two clinical studies92,93 used a part of or entire AUCB. Eventually cellular senescence and life span need more clarification. Senescence of cultured stem cells is another main concern for clinical trials. Prolonged in vitro expansion could set off senescence phenotype and telomere shortening, in this way the stem cell regenerative capacity may very well be modified.Fifty four

Cell supply and dosage

As seen in the research summarized in Table 2, the cell sources are very totally different, with significant properties various from tissue to tissue. Proliferation and expansion potential are affected additionally by donor age.97 The effective cell dosage must be decided more. The optimum stem cell sort for cellular grafts is still uncertain.

Autologous or allogenic transplantation?

The choice between autologous or allogenic transplantation remains a key issue.98 Autologous infusion requires preventive storage of the personal biomaterial, with the associated issues (ie, the fee for the cryostorage). As well as, even when some inherited genetic diseases are handled with stem cells (ie, thalassemia main or extreme combined immune deficiency [SCID] diseases),99 the possibility to deal with the cases of ASDs resulting from genetic defects (nonsyndromic autism)100 is still debated. If some genetic modifications are current within the ASD subject, these adjustments might be kept by all of the stored and biobanked cell sorts. Allogenic transplantation overcomes this latter downside. However, the availability of donors and subsequent infectious disease checks are key factors to be taken into account.

Route of cell administration

Intrathecal route appears to be invasive. However, authors who used this way of administration reported its security and efficient supply of cells to brain, as transplanted cells might attain crucial central nervous system areas by means of cerebrospinal fluid, enhancing cell homing onto broken centers.One zero one

Ethics

Ethics in stem cell therapies, in addition to in ASD administration, require particular consideration.102 Cell therapy should be performed under regulation and approval of regulatory establishments. In the case of unfavourable results from clinical trials, apply of the cell therapy ought to be discontinued.

Another query is the validity of repeated cell treatments. Presently, there is no published evidence of the effectiveness of repeated cell transplantations in ASDs and clinical trials ought to be carried out. Dawson et al highlight that the financial standing could affect cell therapy availability.Ninety three Especially in the case of AUCB, some ethnic teams could not be capable of deal the price of biobanking.

Preclinical evidences highlight potential profit and important advances for the usage of cellular therapy in ASDs. Because the mechanisms by which transplantation of stem cells results in an enhanced purposeful restoration and structural reorganization need to be higher elucidated,sixty one in vivo studies should provide definitive results on the mechanism of motion of stem cells that in some cases it is not attainable to reproduce or research in humans (ie, detailed analysis of secretome process). Initially, the primary concept on mechanism of action of stem cells was that cell therapy might act by a "cell replacement" mechanism; nowadays, large rising evidences have shown that cell therapy works by offering trophic or "chaperone" support to the injured tissue and brain.103 It's noteworthy to consider that the clinical trials on stem cell transplantation in ASD topics clearly point out the security of the procedures (security is the first final result). These studies additionally report important encouraging constructive results in relief of ASD signs (a part of the work of Chez et al,92 as mentioned earlier, the place the authors declare just for a pattern of amelioration) and advocate for the usage of cellular therapy in ASDs. However, thus far, solely five clinical trials have been performed (Table 2) with several differences amongst them (examine design, topics enrolled, cellular sorts, route of administration, end result measures), which will require additional examinations. Taken together the limitation concerns and the promising ameliorative results of cellular therapies in ASD therapy, extra full and exhaustive investigations and large trials will probably be wanted in order to say definitive outcomes.104

Footnotes

Disclosure

The authors report no conflicts of curiosity in this work.

- 1.Courchesne E, Pramparo T, Gazestani VH, Lombardo MV, Pierce K, Lewis NE. The ASD residing biology: from cell proliferation to clinical phenotype. Mol Psychiatry. 2018June:22. doi: 10.1038/s41380-018-0056-y. Epub. [DOI] [PMC free article] [PubMed] [Google Scholar]- 2.Geschwind DH. Advances in autism. Annu Rev Med. 2009;60:367-380. doi: 10.1146/annurev.med.60.053107.121225. [DOI] [PMC free article] [PubMed] [Google Scholar]- 3.Chaste P, Leboyer M. Autism threat components: genes, setting, and gene-setting interactions. Dialogues Clin Neurosci. 2012;14(3):281-292. doi: 10.31887/DCNS.2012.14.3/pchaste. [DOI] [PMC free article] [PubMed] [Google Scholar]- 4.Mottron L, Belleville S, Rouleau GA, Collignon O. Linking neocortical, cognitive, and genetic variability in autism with alterations of mind plasticity: the Trigger-Threshold-Target model. Neurosci Biobehav Rev. 2014;47:735-752. doi: 10.1016/j.neubiorev.2014.07.012. [DOI] [PubMed] [Google Scholar]- 5.Iovene MR, Bombace F, Maresca R, et al. Intestinal dysbiosis and yeast isolation in stool of topics with autism spectrum disorders. Mycopathologia. 2017;182(3-4):349-363. doi: 10.1007/s11046-016-0068-6. [DOI] [PubMed] [Google Scholar]- 6.Rose DR, Yang H, Serena G, et al. Differential immune responses and microbiota profiles in youngsters with autism spectrum disorders and co-morbid gastrointestinal symptoms. Brain Behav Immun. 2018;70:354-368. doi: 10.1016/j.bbi.2018.03.025. [DOI] [PMC free article] [PubMed] [Google Scholar]- 7.Onore C, Careaga M, Ashwood P. The role of immune dysfunction within the pathophysiology of autism. Brain Behav Immun. 2012;26(3):383-392. doi: 10.1016/j.bbi.2011.08.007. [DOI] [PMC free article] [PubMed] [Google Scholar]- 8.Siniscalco D, Schultz S, Brigida AL, Antonucci N. Inflammation and neuroimmune dysregulations in autism spectrum disorders. Pharmaceuticals (Basel) 2018;11(2):E56. doi: 10.3390/ph11020056. [DOI] [PMC free article] [PubMed] [Google Scholar]- 9.Ghaziuddin M, Al-Owain M. Autism spectrum disorders and inborn errors of metabolism: an update. Pediatr Neurol. 2013;49(4):232-236. doi: 10.1016/j.pediatrneurol.2013.05.013. [DOI] [PubMed] [Google Scholar]- 10.Baio J, Wiggins L, Christensen DL, et al. Prevalence of autism spectrum disorder amongst youngsters aged eight years - autism and developmental disabilities monitoring network, eleven websites, united states, 2014. MMWR. Surveill Summ. 2018;67(6):1-23. doi: 10.15585/mmwr.ss6706a1. [DOI] [PMC free article] [PubMed] [Google Scholar]- 11.Elsabbagh M, Divan G, Koh YJ, et al. Global prevalence of autism and different pervasive developmental disorders. Autism Res. 2012;5(3):160-179. doi: 10.1002/aur.239. [DOI] [PMC free article] [PubMed] [Google Scholar]- 12.American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington DC: American Psychiatric Association; 2013. [Google Scholar]- 13.Pratt J, Hall J. Biomarkers in neuropsychiatry: a prospect for the twenty-first Century? Curr Top Behav Neurosci. 2018 Jul 3;7:1-8. doi: 10.1007/7854_2018_58. Epub. [DOI] [PubMed] [Google Scholar]- 14.Thibaut F. New perspectives in autism spectrum disorders. Dialogues Clin Neurosci. 2017;19(4):323. doi: 10.31887/DCNS.2017.19.4/fthibaut. [DOI] [PMC free article] [PubMed] [Google Scholar]- 15.Oberman LM, Rotenberg A, Pascual-Leone A. Use of transcranial magnetic stimulation in autism spectrum disorders. J Autism Dev Disord. 2015;45(2):524-536. doi: 10.1007/s10803-013-1960-2. [DOI] [PMC free article] [PubMed] [Google Scholar]- 16.Rossignol DA, Bradstreet JJ, Van Dyke K, et al. Hyperbaric oxygen remedy in autism spectrum disorders. Med Gas Res. 2012;2(1):16. doi: 10.1186/2045-9912-2-16. [DOI] [PMC free article] [PubMed] [Google Scholar]- 17.Sharma SR, Gonda X, Tarazi FI. Autism spectrum disorder: classification, analysis and therapy. Pharmacol Ther. 2018;190:91-104. doi: 10.1016/j.pharmthera.2018.05.007. [DOI] [PubMed] [Google Scholar]- 18.DemMayo MM, Song YJC, Hickie IB, Guastella AJ. A overview of the safety, efficacy and mechanisms of supply of nasal oxytocin in children: therapeutic potential for autism and Prader-Willi syndrome, and suggestions for future research. Paediatr Drugs. 2017;19(5):391-410. doi: 10.1007/s40272-017-0248-y. [DOI] [PubMed] [Google Scholar]- 19.Gasparotto FM, Dos Reis Lívero FA, Tolouei Menegati SEL, Junior AG. Herbal drugs as an alternative therapy in autism spectrum disorder: a scientific overview. Curr Drug Metab. 2018;19(5):454-459. doi: 10.2174/1389200219666171227202332. [DOI] [PubMed] [Google Scholar]- 20.Adams JB, Audhya T, Geis E, et al. Comprehensive nutritional and dietary intervention for autism spectrum disorder-a randomized, managed 12-month trial. Nutrients. 2018;10(3):E369. doi: 10.3390/nu10030369. [DOI] [PMC free article] [PubMed] [Google Scholar]- 21.Benger M, Kinali M, Mazarakis ND. Autism spectrum disorder: prospects for treatment utilizing gene therapy. Mol Autism. 2018;9:39. doi: 10.1186/s13229-018-0222-8. [DOI] [PMC free article] [PubMed] [Google Scholar]- 22.Siniscalco D, Bradstreet JJ, Sych N, Antonucci N. Perspectives on the use of stem cells for autism remedy. Stem Cells Int. 2013;2013:262438. doi: 10.1155/2013/262438. [DOI] [PMC free article] [PubMed] [Google Scholar]- 23.Song CG, Zhang YZ, Wu HN, et al. Stem cells: a promising candidate to treat neurological disorders. Neural Regen Res. 2018;13(7):1294-1304. doi: 10.4103/1673-5374.235085. [DOI] [PMC free article] [PubMed] [Google Scholar]- 24.Mazzini L, Ferrari D, Andjus PR, et al. BIONECA Cost Action WG Neurology Advances in stem cell therapy for amyotrophic lateral sclerosis. Expert Opin Biol Ther. 2018;18(8):865-881. doi: 10.1080/14712598.2018.1503248. [DOI] [PubMed] [Google Scholar]- 25.Brick DJ, Nethercott HE, Montesano S, et al. The autism spectrum disorders stem cell resource at Children’s Hospital of Orange County: implications for illness modeling and drug discovery. Stem Cells Transl Med. 2014;3(11):1275-1286. doi: 10.5966/sctm.2014-0073. [DOI] [PMC free article] [PubMed] [Google Scholar]- 26.Siniscalco D, Mijatovic T, Bosmans E, et al. Decreased numbers of CD57+CD3- cells determine potential innate immune differences in patients with autism spectrum disorder. In Vivo. 2016;30(2):83-89. [PubMed] [Google Scholar]- 27.Inga Jácome MC, Morales Chacòn LM, Vera Cuesta H, et al. Peripheral inflammatory markers contributing to comorbidities in autism. Behav Sci (Basel) 2016;6(4):E29. doi: 10.3390/bs6040029. [DOI] [PMC free article] [PubMed] [Google Scholar]- 28.Brigida AL, Schultz S, Cascone M, Antonucci N, Siniscalco D. Endocannabinod sign dysregulation in autism spectrum disorders: a correlation link between inflammatory state and neuroimmune alterations. Int J Mol Sci. 2017;18(7):E1425. doi: 10.3390/ijms18071425. [DOI] [PMC free article] [PubMed] [Google Scholar]- 29.Siniscalco D, Sapone A, Giordano C, et al. The expression of caspases is enhanced in peripheral blood mononuclear cells of autism spectrum disorder patients. J Autism Dev Disord. 2012;42(7):1403-1410. doi: 10.1007/s10803-011-1373-z. [DOI] [PubMed] [Google Scholar]- 30.Siniscalco D, Sapone A, Giordano C, et al. Cannabinoid receptor type 2, however not type 1, is up-regulated in peripheral blood mononuclear cells of youngsters affected by autistic disorders. J Autism Dev Disord. 2013;43(11):2686-2695. doi: 10.1007/s10803-013-1824-9. [DOI] [PubMed] [Google Scholar]- 31.Caprnda M, Kubatka P, Gazdikova K, et al. Immunomodulatory results of stem cells: therapeutic option for neurodegenerative disorders. Biomed Pharmacother. 2017;91:60-69. doi: 10.1016/j.biopha.2017.04.034. [DOI] [PubMed] [Google Scholar]- 32.Siniscalco D, Giordano C, Galderisi U, et al. Long-lasting results of human mesenchymal stem cell systemic administration on pain-like behaviors, cellular, and biomolecular modifications in neuropathic mice. Front Integr Neurosci. 2011;5:79. doi: 10.3389/fnint.2011.00079. [DOI] [PMC free article] [PubMed] [Google Scholar]- 33.Guillot PV, Gotherstrom C, Chan J, Kurata H, Fisk NM. Human first-trimester fetal MSC express pluripotency markers and grow quicker and have longer telomeres than grownup MSC. Stem Cells. 2007;25(3):646-654. doi: 10.1634/stemcells.2006-0208. [DOI] [PubMed] [Google Scholar]- 34.Lee H, Yun S, Kim IS, et al. Human fetal brain-derived neural stem/progenitor cells grafted into the adult epileptic mind restrain seizures in rat models of temporal lobe epilepsy. PLoS One. 2014;9(8):e104092. doi: 10.1371/journal.pone.0104092. [DOI] [PMC free article] [PubMed] [Google Scholar]- 35.Kelly S, Bliss TM, Shah AK, et al. Transplanted human fetal neural stem cells survive, migrate, and differentiate in ischemic rat cerebral cortex. Proc Natl Acad Sci U S A. 2004;101(32):11839-11844. doi: 10.1073/pnas.0404474101. [DOI] [PMC free article] [PubMed] [Google Scholar]- 36.Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson’s illness. N Engl J Med. 2001;344(10):710-719. doi: 10.1056/NEJM200103083441002. [DOI] [PubMed] [Google Scholar]- 37.Bradstreet JJ, Sych N, Antonucci N, et al. Efficacy of fetal stem cell transplantation in autism spectrum disorders: an open-labeled pilot research. Cell Transplant. 2014;23(1 Suppl):S105-S112. doi: 10.3727/096368914X684916. [DOI] [PubMed] [Google Scholar]- 38.Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position assertion. Cytotherapy. 2006;8(4):315-317. doi: 10.1080/14653240600855905. [DOI] [PubMed] [Google Scholar]- 39.Giordano A, Galderisi U, Marino IR. From the laboratory bench to the patient’s bedside: an replace on clinical trials with mesenchymal stem cells. J Cell Physiol. 2007;211(1):27-35. doi: 10.1002/jcp.20959. [DOI] [PubMed] [Google Scholar]- 40.Katuchova J, Harvanova D, Spakova T, et al. Mesenchymal stem cells in the therapy of kind 1 diabetes mellitus. Endocr Pathol. 2015;26(2):95-103. doi: 10.1007/s12022-015-9362-y. [DOI] [PubMed] [Google Scholar]- 41.Siniscalco D, Bradstreet JJ, Sych N, Antonucci N. Mesenchymal stem cells in treating autism: Novel insights. World J Stem Cells. 2014;6(2):173-178. doi: 10.4252/wjsc.v6.i2.173. [DOI] [PMC free article] [PubMed] [Google Scholar]- 42.Liang CM, Weng SJ, Tsai TH, et al. Neurotrophic and neuroprotective potential of human limbus-derived mesenchymal stromal cells. Cytotherapy. 2014;16(10):1371-1383. doi: 10.1016/j.jcyt.2014.05.015. [DOI] [PubMed] [Google Scholar]- 43.Klyushnenkova E, Mosca JD, Zernetkina V, et al. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci. 2005;12(1):47-57. doi: 10.1007/s11373-004-8183-7. [DOI] [PubMed] [Google Scholar]- 44.Jacobs SA, Roobrouck VD, Verfaillie CM, Van Gool SW. Immunological characteristics of human mesenchymal stem cells and multipotent grownup progenitor cells. Immunol Cell Biol. 2013;91(1):32-39. doi: 10.1038/icb.2012.64. [DOI] [PMC free article] [PubMed] [Google Scholar]- 45.Siniscalco D, Sapone A, Cirillo A, Giordano C, Maione S, Antonucci N. Autism spectrum disorders: is mesenchymal stem cell personalised therapy the long run? J Biomed Biotechnol. 2012;2012:480289. doi: 10.1155/2012/480289. [DOI] [PMC free article] [PubMed] [Google Scholar]- 46.Kassis I, Vaknin-Dembinsky A, Karussis D. Bone marrow mesenchymal stem cells: brokers of immunomodulation and neuroprotection. Curr Stem Cell Res Ther. 2011;6(1):63-68. doi: 10.2174/157488811794480762. [DOI] [PubMed] [Google Scholar]- 47.Karussis D, Petrou P, Kassis I. Clinical expertise with stem cells and other cell therapies in neurological diseases. J Neurol Sci. 2013;324(1-2):1-9. doi: 10.1016/j.jns.2012.09.031. [DOI] [PubMed] [Google Scholar]- 48.Lv YT, Zhang Y, Liu M, et al. Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism. J Transl Med. 2013;11:196. doi: 10.1186/1479-5876-11-196. [DOI] [PMC free article] [PubMed] [Google Scholar]- 49.Bourin P, Bunnell BA, Casteilla L, et al. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT) Cytotherapy. 2013;15(6):641-648. doi: 10.1016/j.jcyt.2013.02.006. [DOI] [PMC free article] [PubMed] [Google Scholar]- 50.Frese L, Dijkman PE, Hoerstrup SP. Adipose tissue-derived stem cells in regenerative medicine. Transfus Med Hemother. 2016;43(4):268-274. doi: 10.1159/000448180. [DOI] [PMC free article] [PubMed] [Google Scholar]- 51.Zhou F, Gao S, Wang L, et al. Human adipose-derived stem cells partially rescue the stroke syndromes by selling spatial learning and reminiscence in mouse middle cerebral artery occlusion model. Stem Cell Res Ther. 2015;6:92. doi: 10.1186/s13287-015-0078-1. [DOI] [PMC free article] [PubMed] [Google Scholar]- 52.Ding DC, Chang YH, Shyu WC, Lin SZ. Human umbilical cord mesenchymal stem cells: a new period for stem cell therapy. Cell Transplant. 2015;24(3):339-347. doi: 10.3727/096368915X686841. [DOI] [PubMed] [Google Scholar]- 53.Xu Y, Huang S, Ma K, Fu X, Han W, Sheng Z. Promising new potential for mesenchymal stem cells derived from human umbilical cord Wharton’s jelly: sweat gland cell-like differentiative capacity. J Tissue Eng Regen Med. 2012;6(8):645-654. doi: 10.1002/time period.468. [DOI] [PubMed] [Google Scholar]- 54.Alessio N, Pipino C, Mandatori D, et al. Mesenchymal stromal cells from amniotic fluid are less prone to senescence compared to those obtained from bone marrow: an in vitro study. J Cell Physiol. 2018;233(11):8996-9006. doi: 10.1002/jcp.26845. [DOI] [PubMed] [Google Scholar]- 55.Witkowska-Zimny M, Wrobel E. Perinatal sources of mesenchymal stem cells: Wharton’s jelly, amnion and chorion. Cell Mol Biol Lett. 2011;16(3):493-514. doi: 10.2478/s11658-011-0019-7. [DOI] [PMC free article] [PubMed] [Google Scholar]- 56.Stevens HE, Smith KM, Rash BG, Vaccarino FM. Neural stem cell regulation, fibroblast development factors, and the developmental origins of neuropsychiatric disorders. Front Neurosci. 2010;4:59. doi: 10.3389/fnins.2010.00059. [DOI] [PMC free article] [PubMed] [Google Scholar]- 57.Reynolds BA, Weiss S. Generation of neurons and astrocytes from isolated cells of the grownup mammalian central nervous system. Science. 1992;255(5052):1707-1710. doi: 10.1126/science.1553558. [DOI] [PubMed] [Google Scholar]- 58.Palmer TD, Ray J, Gage FH. FGF-2-responsive neuronal progenitors reside in proliferative and quiescent areas of the grownup rodent brain. Mol Cell Neurosci. 1995;6(5):474-486. doi: 10.1006/mcne.1995.1035. [DOI] [PubMed] [Google Scholar]- 59.Buxbaum JD. Multiple uncommon variants within the etiology of autism spectrum disorders. Dialogues Clin Neurosci. 2009;11(1):35-43. doi: 10.31887/DCNS.2009.11.1/jdbuxbaum. [DOI] [PMC free article] [PubMed] [Google Scholar]- 60.Hsu YC, Lee DC, Chiu IM. Neural stem cells, neural progenitors, and neurotrophic elements. Cell Transplant. 2007;16(2):133-150. [PubMed] [Google Scholar]- 61.Kim SU, de Vellis J. Stem cell-primarily based cell therapy in neurological diseases: a evaluation. J Neurosci Res. 2009;87(10):2183-2200. doi: 10.1002/jnr.22054. [DOI] [PubMed] [Google Scholar]- 62.Liu SP, Fu RH, Huang SJ, et al. Stem cell purposes in regenerative drugs for neurological disorders. Cell Transplant. 2013;22(4):631-637. doi: 10.3727/096368912X655145. [DOI] [PubMed] [Google Scholar]- 63.Siniscalco D, Bradstreet JJ, Antonucci N. Therapeutic role of hematopoietic stem cells in autism spectrum disorder-associated inflammation. Front Immunol. 2013;4:140. doi: 10.3389/fimmu.2013.00140. [DOI] [PMC free article] [PubMed] [Google Scholar]- 64.Brigida AL, Siniscalco D. Induced pluripotent stem cells as a cellular model for learning Down Syndrome. J Stem Cells Regen Med. 2016;12(2):54-60. doi: 10.46582/jsrm.1202009. [DOI] [PMC free article] [PubMed] [Google Scholar]- 65.Park IH, Arora N, Huo H, et al. Disease-specific induced pluripotent stem cells. Cell. 2008;134(5):877-886. doi: 10.1016/j.cell.2008.07.041. [DOI] [PMC free article] [PubMed] [Google Scholar]- 66.Medvedev SP, Shevchenko AI, Zakian SM. Induced pluripotent stem cells: issues and advantages when making use of them in regenerative medicine. Acta Naturae. 2010;2(2):18-28. [PMC free article] [PubMed] [Google Scholar]- 67.Nori S, Okada Y, Yasuda A, et al. Grafted human-induced pluripotent stem-cell-derived neurospheres promote motor functional restoration after spinal cord injury in mice. Proc Natl Acad Sci U S A. 2011;108(40):16825-16830. doi: 10.1073/pnas.1108077108. [DOI] [PMC free article] [PubMed] [Google Scholar]- 68.Hallett PJ, Deleidi M, Astradsson A, et al. Successful operate of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate mannequin of Parkinson’s disease. Cell Stem Cell. 2015;16(3):269-274. doi: 10.1016/j.stem.2015.01.018. [DOI] [PMC free article] [PubMed] [Google Scholar]- 69.Jeon I, Choi C, Lee N, et al. In vivo roles of a patient-derived induced pluripotent stem cell line (HD72-iPSC) within the YAC128 model of Huntington’s illness. Int J Stem Cells. 2014;7(1):43-47. doi: 10.15283/ijsc.2014.7.1.43. [DOI] [PMC free article] [PubMed] [Google Scholar]- 70.Nizzardo M, Simone C, Rizzo F, et al. Minimally invasive transplantation of iPSC-derived ALDHhiSSCloVLA4+ neural stem cells effectively improves the phenotype of an amyotrophic lateral sclerosis mannequin. Hum Mol Genet. 2014;23(2):342-354. doi: 10.1093/hmg/ddt425. [DOI] [PMC free article] [PubMed] [Google Scholar]- 71.Knoepfler PS. Deconstructing stem cell tumorigenicity: a roadmap to protected regenerative drugs. Stem Cells. 2009;27(5):1050-1056. doi: 10.1002/stem.37. [DOI] [PMC free article] [PubMed] [Google Scholar]- 72.Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature. 2011;474(7350):212-215. doi: 10.1038/nature10135. [DOI] [PubMed] [Google Scholar]- 73.Ben-Reuven L, Reiner O. Modeling the autistic cell: iPSCs recapitulate developmental principles of syndromic and nonsyndromic ASD. Dev Growth Differ. 2016;58(5):481-491. doi: 10.1111/dgd.12280. [DOI] [PubMed] [Google Scholar]- 74.Varga E, Nemes C, Bock I, et al. Establishment of an induced pluripotent stem cell (iPSC) line from a 9-12 months outdated male with autism spectrum disorder (ASD) Stem Cell Res. 2017;21:19-22. doi: 10.1016/j.scr.2017.03.013. [DOI] [PubMed] [Google Scholar]- 75.Lim CS, Yang JE, Lee YK, Lee K, Lee JA, Kaang BK. Understanding the molecular foundation of autism in a dish utilizing hiPSCs-derived neurons from ASD patients. Mol Brain. 2015;8(1):57. doi: 10.1186/s13041-015-0146-6. [DOI] [PMC free article] [PubMed] [Google Scholar]- 76.Kim DS, Ross PJ, Zaslavsky K, Ellis J. Optimizing neuronal differentiation from induced pluripotent stem cells to mannequin ASD. Front Cell Neurosci. 2014;8:109. doi: 10.3389/fncel.2014.00109. [DOI] [PMC free article] [PubMed] [Google Scholar]- 77.Griesi-Oliveira K, Acab A, Gupta AR, et al. Modeling non-syndromic autism and the affect of TRPC6 disruption in human neurons. Mol Psychiatry. 2015;20(11):1350-1365. doi: 10.1038/mp.2014.141. [DOI] [PMC free article] [PubMed] [Google Scholar]- 78.Liu X, Campanac E, Cheung HH, et al. Idiopathic autism: cellular and molecular phenotypes in pluripotent stem cell-derived neurons. Mol N